Higher research and development expenses were driven by increased clinical trial and contract manufacturing costs as the company advanced clinical programs and prepared for regulatory filings
Higher general and administrative expenses were mainly due to additional pre-commercialization activities for ozekibart
The increase in other expense, net, was mainly due to higher interest expense on the outstanding loan balance
Quarterly results
US biopharmaceutical firm's Q2 2026 revenue was zero, down from the prior-year period
Net loss for Q2 widened year over year as operating expenses increased
Q2 loss per share was $2.34, versus consensus of $2.39 from two analysts
Q2 net loss was $36.65 million, versus consensus of $29.62 million from two analysts
Cash and analyst coverage
The company secured $100 million in loan proceeds after quarter-end, increasing its cash position
The current average analyst rating on the shares is buy and the breakdown of recommendations is , and
INBX•
